Antiproliferative activity of NQ304, a synthetic 1,4-naphthoquinone, is mediated via the suppressions of the PI3K/Akt and ERK1/2 signaling pathways in PDGF-BB-stimulated vascular smooth muscle cells

Vascular Pharmacology

Volumn 46, Issue 1, 2007, Pages 43-51

  Kim, Tack Joong ^a   Yun, Yeo Pyo ^a  

^a Chungbuk National University   (South Korea)

Author keywords

1,4 Naphthoquinone; Cardiovascular disease; Extracellular signal regulated kinase; NQ304; Phosphatidylinositol 3 kinase; Platelet derived growth factor; Vascular smooth muscle cell

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2 CHLORO 3 (4 HEXYLPHENYL)AMINO 1,4 NAPHTHOQUINONE; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL STIMULATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE EXPRESSION; INCUBATION TIME; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; AORTA; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE; GROWTH INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NAPHTHOQUINONES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR AP-1;

EID: 33845285922     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.06.007     Document Type: Article

References (44)

1. Ahn H.Y., Hadizadeh K.R., Seul C., Yun Y.P., Vetter H., and Sachinidis A. Epigallocatechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol. Biol. Cell 10 (1999) 1093-1104
2. Belinsky S.A., Middleton S.K., Picksley S.M., Hahn F.F., and Nikula K.J. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat. Radiat. Res. 145 (1996) 449-456
3. Chamley J.H., Campbell G.R., McConnell J.D., and Groschel-Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res. 177 (1977) 503-522
4. Chlebowski R.T., Dietrich M., Akman S., and Block J.B. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat. Rep. 69 (1985) 527-532
5. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J. Biol. Chem. 269 (1994) 32023-32026
6. Curran T., Gordon M.B., Rubino K.L., and Sambucetti L.C. Isolation and characterization of the c-fos (rat) cDNA and analysis of post-translational modification in vitro. Oncogene 2 (1987) 79-84
7. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
8. Davis R.J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268 (1993) 14553-14556
9. Dimmeler S., Assmus B., Hermann C., Haendeler J., and Zeiher A.M. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ. Res. 83 (1998) 334-341
10. Fort P., Marty L., Piechaczyk M., el Sabrouty S., Dani C., and Jeanteur P. Blanchard JM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 13 (1985) 1431-1442
11. Graf K., Xi X.P., Yang D., Fleck E., Hsueh W.A., and Law R.E. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 29 (1997) 334-339
12. Heldin C.H., Ostman A., and Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1378 (1998) F79-F113
13. Higaki M., and Shimokado K. Phosphatidylinositol 3-kinase is required for growth factor-induced amino acid uptake by vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2127-2132
14. Ishikawa T., Kotake K., and Ishii H. Synthesis of toddacoumaquinone, a coumarin-naphthoquinone dimer, and its antiviral activities. Chem. Pharm. Bull. (Tokyo) 43 (1995) 1039-1041
15. Jin Y.R., Cho M.R., Ryu C.K., Chung J.H., Yuk D.Y., Hong J.T., Lee K.S., Lee J.J., Lee M.Y., Lim Y., and Yun Y.P. Antiplatelet activity of J78 (2-chloro-3-[2′-bromo, 4′-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. J. Pharmacol. Exp. Ther. 312 (2005) 214-219
16. Kar S., and Carr B.I. Growth inhibition and protein tyrosine phosphorylation in MCF7 breast cancer cells by a novel K vitamin. J. Cell. Physiol. 185 (2000) 386-393
17. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., and Evan G. Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB. Nature 385 (1997) 544-548
18. Kawada M., Yamagoe S., Murakami Y., Suzuki K., Mizuno S., and Uehara Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15 (1997) 629-637
19. Kim T.J., Zhang Y.H., Kim Y., Lee C.K., Lee M.K., Hong J.T., and Yun Y.P. Effects of apigenin on the serum- and platelet-derived growth factor-BB-induced proliferation of rat aortic vascular smooth muscle cells. Planta Med. 68 (2002) 605-609
20. Ko F.N., Sheu S.J., Liu Y.M., Huang T.F., and Teng C.M. Inhibition of rabbit platelet aggregation by 1,4-naphthoquinones. Thromb. Res. 57 (1990) 453-463
21. Koyama H., Olson N.E., Dastvan F.F., and Reidy M.A. Cell replication in the arterial wall: activation of signaling pathway following in vivo injury. Circ. Res. 82 (1998) 713-721
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
23. Li X.A., Bianchi C., and Sellke F.W. Rat aortic smooth muscle cell density affects activation of MAP kinase and Akt by menadione and PDGF homodimer BB. J. Surg. Res. 100 (2001) 197-204
24. Lipson K.E., Pang L., Huber L.J., Chen H., Tsai J.M., Hirth P., Gazit A., Levitzki A., and McMahon G. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J. Pharmacol. Exp. Ther. 285 (1998) 844-852
25. Majesky M.W., Reidy M.A., Bowen-Pope D.F., Hart C.E., Wilcox J.N., and Schwartz S.M. PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell Biol. 111 (1990) 2149-2158
26. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
27. Mulvany M.J. Structure and function of small arteries in hypertension. J. Hypertens. 8 (1990) 225-232
28. Myllärniemi M., Frösen J., Calderón Ramirez L.G., Buchdunger E., Lemström K., and Häyry P. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther. 13 (1999) 159-168
29. Oh J.H., Jung H.K., Park Y.J., Kim C.K., Chung S.Y., Park N.G., Yun Y.W., Kim D.J., Ha T.Y., Song Y.S., Lee Y.M., Oh K., and Hong J.T. Inhibitory effects of ochratoxin A on nerve growth factor-induced neurite extension through downregulation of p38 MAP kinase and AP-1 activation in cultured pheochromocytoma cells. J. Toxicol. Environ. Health A 67 (2004) 357-371
30. Pyles J.M., March K.L., Franklin M., Mehdi K., Wilensky R.L., and Adam L.P. Activation of MAP kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries. Circ. Res. 8 (1997) 904-910
31. Rao G.N., and Berk B.C. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ. Res. 70 (1992) 593-599
32. Rodriguez S., Wolfender J.L., Hakizamungu E., and Hostettmann K. An antifungal naphthoquinone, xanthones and secoiridoids from Swertia calycina. Planta Med. 61 (1995) 362-364
33. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
34. Ross R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57 (1995) 791-804
35. Ryu C.K. Synthesis of anticoagulant 2-chloro-3(N-arylamino)-1,4-naphthoquinones. Yakhak Hoeji 32 (1988) 245-250
36. Sachinidis A., Locher R., Vetter W., Tatje D., and Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J. Biol. Chem. 265 (1990) 10238-10243
37. Shen A.Y., Huang M.H., Teng C.M., and Wang J.S. Inhibition of 2-P-mercaptophenyl-1,4-naphthoquinone on human platelet function. Life Sci. 65 (1999) 45-53
38. Sherr C.J. G1 phase progression: cycling on cue. Cell 79 (1994) 551-555
39. Tamura K., Southwick E.C., Kerns J., Rosi K., Carr B.I., Wilcox C., and Lazo J.S. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 60 (2000) 1317-1325
40. Tanner F.C., Yang Z.Y., and Gordon D. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82 (1998) 396-403
41. Waltenberger J. Modulation of growth factor action. Implications for the treatment of cardiovascular diseases. Circulation 96 (1997) 4083-4094
42. Watson M.H., Venance S.L., Pang S.C., and Mak A.S. Smooth muscle cell proliferation. Expression and kinase activities of p34cdc2 and mitogen-activated protein kinase homologues. Circ. Res. 73 (1993) 109-117
43. Yuk D.Y., Lee H.Y., Ryu C.K., Hong J.T., Kang W.S., Yoo H.S., and Yun Y.P. Studies on the antithrombotic and antiplatelet activities of NQ304, a newly synthesized naphthoquinone derivative. Arzneimittelforschung 50 (2000) 254-259
44. Zhang Y.H., Chung K.H., Ryu C.K., Lee Y.H., Kim T.J., Song Y.S., Hwang K.A., and Yun Y.P. Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone (NQ304), an antithrombotic agent. Pharmacol. Toxicol. 88 (2001) 181-186